What can actually be done?

What symptoms are we talking about?

Male LUTS may include:

• weak stream;
• hesitancy;
• stopping and starting;
• straining;
• incomplete emptying;
• urgency;
• frequency;
• leakage;
• nocturia;
• post-urination dribbling.

These symptoms are commonly associated with benign prostate enlargement, but the bladder and other factors may also contribute. Treatment works best when it targets the dominant mechanism rather than simply treating the word “prostate”.

What is the first treatment?

For many men, the first treatment is not surgery.

Current European guideline pathways include watchful waiting, behavioural modification, medication and a range of procedures.¹ The choice is based on symptom burden, objective findings, risk of progression and patient preference.

For mild symptoms, active self-management may be enough. For more troublesome symptoms, medication or a procedure may be appropriate.

Does self-management actually work?

It can.

A 2021 systematic review and meta-analysis included eight studies involving 1,006 men.³ Compared with usual care, structured self-management produced a clinically important reduction in symptom severity. In two studies reporting six-month outcomes, the mean improvement on the 35-point International Prostate Symptom Score (IPSS) was 7.4 points greater than usual care (95% confidence interval 6.1–8.8 points).³

That is a meaningful effect. The review also found that, over shorter follow-up, self-management could achieve symptom improvement of a similar order to drug therapy in some comparisons.³

However, the studies used different self-management programmes and several had risk-of-bias concerns, so the result should not be interpreted as “lifestyle changes always work as well as medication”.³

What does self-management include?

Depending on the symptom pattern, it can involve:

• adjusting the timing of fluid intake;
• reducing excessive evening drinking;
• moderating caffeine or alcohol when they clearly worsen symptoms;
• addressing constipation;
• bladder training for urgency;
• strategies for post-void dribbling;
• reviewing medicines that worsen urinary symptoms;
• changing the timing of diuretics where appropriate and medically safe.

The aim is targeted behaviour change, not simply telling a patient to “drink less”.

What medications can help?

Different medicines target different parts of the problem.

Alpha-blockers

These relax smooth muscle around the prostate and bladder outlet. They tend to work relatively quickly and can improve both flow-related and overall urinary symptoms. They do not shrink the prostate.

5-alpha-reductase inhibitors

These can reduce prostate volume over time in appropriately selected men with enlarged prostates. Their effect is slower, but they may reduce the longer-term risk of urinary retention or surgery in men at higher risk of progression.

Bladder-directed medicines

When urgency and frequency dominate, treatment may target the bladder rather than—or in addition to—the prostate.

Combination treatment

Some men benefit from more than one drug class when several mechanisms coexist.

Guidelines emphasise that medication choice should reflect the clinical profile, likely benefits, side effects and expectations.¹

Which side effects matter most to patients?

This is not a minor issue.

A systematic review of 29 studies involving 9,235 patients found that men place substantial value on avoiding sexual side effects and on improvements in urgency, incontinence and nocturia.² They also care about reducing the risk of acute urinary retention or future surgery.²

This explains why the “best” treatment on a symptom-score chart may not be the best treatment for an individual patient.

For example, one man may prioritise the strongest and most durable relief from obstruction. Another may accept a smaller average improvement in exchange for a better chance of preserving ejaculation.

What are minimally invasive treatments?

Minimally invasive surgical treatments sit between tablets and more conventional tissue-removing operations. They aim to improve the prostatic channel using techniques that may involve implants, thermal treatment, water-based treatment or other forms of tissue modification.

A European review highlighted how these technologies broaden the treatment options for men with LUTS.⁴

However, “minimally invasive” does not automatically mean “better”. Important trade-offs include:

• degree of symptom improvement;
• improvement in urinary flow;
• speed of recovery;
• need for a catheter;
• ejaculation outcomes;
• prostate size and shape limitations;
• durability;
• probability of needing another procedure later.

The evidence base for individual procedures varies considerably. Some have randomised trials and longer-term data; others have smaller or shorter studies.

When is surgery considered?

Surgery is commonly considered when:

• symptoms remain troublesome despite conservative treatment;
• medication is ineffective or causes unacceptable side effects;
• a patient prefers a more definitive solution;
• significant obstruction is present;
• complications such as recurrent retention, bladder stones or other consequences of obstruction develop.

Modern guideline frameworks include several surgical families: resection, enucleation, vaporisation and other ablative or non-ablative approaches.¹

The appropriate operation depends on prostate volume, anatomy, bleeding risk, anaesthetic considerations, the surgeon's expertise and the patient's priorities.

How much better can symptoms get?

There is no single answer because the treatment spectrum is so broad.

Structured self-management alone can produce meaningful average IPSS improvement in selected men.³ Medication usually produces moderate improvements. Tissue-removing operations generally produce larger improvements in symptoms and urinary flow, but with different recovery profiles and risks. Minimally invasive therapies often sit somewhere between those categories, depending on the technique.

The most useful comparison therefore uses several outcomes—not just symptom score:

• IPSS change;
• urinary flow (Qmax, the maximum flow rate);
• post-void residual urine;
• quality of life;
• catheter duration;
• recovery time;
• ejaculation and erection outcomes;
• retreatment rates;
• duration of follow-up.

How quickly does treatment work?

Again, it depends on the treatment.

• Behavioural strategies may help within days to weeks if there is a clear trigger.
• Alpha-blockers generally act relatively quickly.
• Prostate-shrinking medication works over months.
• Surgical procedures can improve obstruction rapidly, although swelling and irritation during recovery may temporarily obscure the eventual benefit.

When discussing a treatment, “how long until I feel better?” is just as important as “does it work eventually?”.

How durable are the results?

Durability varies widely.

A medication works while it is being taken. Some minimally invasive procedures have a meaningful risk of future retreatment. Tissue-removing surgery may offer greater durability but usually involves a more invasive procedure and different side effects.

This is why longer-term follow-up matters. A treatment with excellent results at three months cannot automatically be assumed to have the same durability at five or ten years.

What happens to erections and ejaculation?

This depends strongly on the treatment.

Many prostate procedures have little direct effect on erectile function for most men, but ejaculation can be affected much more commonly by procedures that alter the bladder neck or remove a large amount of prostate tissue. Some newer treatments were specifically designed to reduce the risk of ejaculatory dysfunction, though often with trade-offs in efficacy, durability or anatomical suitability.

Patients' preference research confirms that sexual side effects are a major part of treatment decision-making.²

Who might be a good candidate for treatment?

A good candidate is not simply “a man with a large prostate”. Treatment is most likely to help when:

• symptoms are genuinely bothersome;
• the likely mechanism has been identified;
• anatomy matches the proposed treatment;
• expected benefit is meaningful to the patient;
• the risks and alternatives have been discussed;
• the patient's priorities are reflected in the choice.

How strong is the evidence?

The overall treatment framework is supported by major evidence-based guidelines.¹ Patient-preference evidence comes from systematic review but was judged low to moderate certainty.² Evidence for structured self-management is supported by randomised trials and meta-analysis, although the interventions and study quality varied.³

Evidence for individual minimally invasive technologies varies and continues to evolve.⁴ A balanced treatment discussion should therefore distinguish mature long-term evidence from newer technologies with shorter follow-up.

Bottom line

The idea that “nothing can be done” about male urinary symptoms is outdated.

There is a broad evidence-based treatment spectrum—from structured self-management and medication to minimally invasive procedures and highly effective surgical treatments.^{1, 3} The challenge is not finding a treatment. It is identifying which problem is causing the symptoms and which treatment offers the right balance of effectiveness, durability, recovery and sexual side effects for that particular patient.

The question I am asked most often is which treatment is best. It is the wrong question, and I say so gently. The right one is which trade-off you are willing to make, because every one of these operations costs you something — completeness, ejaculation, recovery time, or the chance of needing something further. My job is to tell you what each one costs before you agree to it, not after.